Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 23.98 |
| Open | 24.95 |
| Bid | 24.80 x 800 |
| Ask | 25.13 x 800 |
| Day's range | 23.37 - 25.89 |
| 52-week range | 15.72 - 146.16 |
| Volume | |
| Avg. volume | 1,578,801 |
| Market cap | 1.008B |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 01 Aug 2022 - 05 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | 72.50 |
- GlobeNewswire
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.
- GlobeNewswire
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
- Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese
